NYAS Conferences
New York Academy of Sciences
left end
Search
divider divider feedback right end
Annals of the New York Academy of Sciences Annals of the New York Academy of Sciences login

Main

Browse Volumes

Forthcoming Volumes

Annals PrePrints

Annals Extra

E-mail Alerts

Subscriptions & Orders

New Proposals

Author Guidelines

About Annals

Help

Get free Annals volume as a NYAS member: http://www.nyas.org/annalsreaderhw
Issue 1089 coverEstrogens and Human Diseases Volume 1089 published November 2006
Ann. N.Y. Acad. Sci. 1089: 237–251 (2006). doi: 10.1196/annals.1386.022
Copyright © 2006 by the New York Academy of Sciences
description | purchase volume purchase this volume

This Volume
Table of Contents
Description
This Article
Full Text
Full Text (PDF)
Services
Similar articles in this journal
Similar articles in PubMed
Alert me to new issues of the journal
Download to citation manager
Citing Articles
Citing Articles via HighWire
Citing Articles via Google Scholar
Google Scholar
Articles by HONG, Y.
Articles by CHEN, S.
Search for Related Content
PubMed
PubMed Citation
Articles by HONG, Y.
Articles by CHEN, S.

Part V. Estrogen and Cancer III—Liver Cancer

Aromatase Inhibitors

Structural Features and Biochemical Characterization

YANYAN HONGa AND SHIUAN CHENa

a Department of Surgical Research, Beckman Research Institute of the City of Hope, Duarte, California 91010, USA

Key Words: breast cancer • aromatase inhibitors • flavonoid phytoestrogen • mechanism-based inhibitor • structural model

Address for correspondence: Dr. Shiuan Chen, Department of Surgical Research, Beckman Research Institute of the City of Hope, 1500 E. Duarte Rd., Duarte, CA 91010. Voice: 626-359-8111; ext. 63454; fax: 626-301-8972.  e-mail: schen{at}coh.org

Aromatase is the enzyme synthesizing estrogens from androgens. In estrogen-dependent breast tumors, estrogens induce the expression of growth factors responsible for cancer cell proliferation. In situ estrogen synthesis by aromatase "is thought to play a key role in the promotion of breast cancer growth. Aromatase inhibitors (AIs) provide new approaches for the prevention and treatment of breast cancer by inhibiting estrogen biosynthesis. Through reverse transcription polymerase chain reaction (RT-PCR) and immunohistochemical techniques, aromatase has been found to be expressed in many endocrine tissues and tumors originating from these tissues. Unexpectedly, this enzyme is now known to also be expressed in liver, lung, and colon cancers. Such findings suggest a potential role for endocrine manipulation of these types of cancer using AIs. Three Food and Drug Administration (FDA)-approved AIs, anastrozole (Arimidex), letrozole (Femara), and exemestane (Aromasin), effectively challenging tamoxifen, have been used as first-line drugs in the treatment of hormone-dependent breast cancer, and possibly other aromatase-expressing cancers. In addition, natural anti-aromatase chemicals, such as flavones and coumarins, have been identified. Efforts to develop new lines of AIs derived from these phytochemicals have been initiated in several laboratories. Finally, significant progress has been made in the understanding of the structure–function relationship of aromatase. Such information has helped the examination of binding characteristics of AIs, the evaluation of reaction mechanism of aromatase, and the explanation of the molecular basis for a low catalytic activity of the natural variant, M364T.




This article has been cited by other articles:


Home page
Endocr Relat CancerHome page
R. Ponzone, P. Mininanni, E. Cassina, F. Pastorino, and P. Sismondi
Aromatase inhibitors for breast cancer: different structures, same effects?
Endocr. Relat. Cancer, March 1, 2008; 15(1): 27 - 36.
[Abstract] [Full Text] [PDF]



footerLeft footerRight